Papadopoulos KP, Owonikoko TK, Johnson ML, Brana I, Gil-Martin M, Perez RP, Moreno V, Salama AK, Calvo E, Yee NS, Safran H, Gonzalez-Martin A, Aljumaily R, Mahadevan D, Mohan KK, Li J, Stankevich E, Lowy I, Fury MG, Homsi J. Cemiplimab (REGN2810), a Fully Human Anti-PD-1 Monoclonal Antibody, for Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: Initial Safety and Efficacy from Expansion Cohorts of Phase 1 Study. J of Skin [Internet]. 2018Feb.23 [cited 2024Jul.22];2(S1):S45. Available from: https://jofskin.org/index.php/skin/article/view/301